ARS Pharmaceuticals Inc (NAS:SPRY)
$ 8.88 -0.1 (-1.11%) Market Cap: 860.43 Mil Enterprise Value: 646.70 Mil PE Ratio: 0 PB Ratio: 3.87 GF Score: 19/100

Silverback Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) Transcript

Feb 16, 2022 / 06:00PM GMT
Daina Graybosch
SVB Securities LLC - Analyst

Hello, everyone. Welcome to the first post-launch for East Coast people -- session at our Global Healthcare Conference. My name is Daina Graybosch. I'm the immuno-oncology analyst here. And I am excited to welcome the management team from Silverback Therapeutics: Laura, Valerie, and Jonathan.

(Conference Instructions)

And with that, maybe I'll turn over to Laura first question, a very high level. If you could just spend a couple of minutes on what is Silverback for people who don't know your story deeply, and then we'll get more into the specific programs and platforms.

Laura Shawver
Silverback Therapeutics, Inc. - CEO

Sure. Great, Daina. Thanks for the opportunity to tell the Silverback story. So Silverback is a platform company focused on ImmunoTAC platform, which is the opportunity to mix and match different antibodies with linker-payloads. And, of course, these antibody drug conjugates, as they're typically called, are very popular these days.

For Silverback, our antibody drug

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot